The FDA has approved a new combination product for the treatment of type 2 diabetes mellitus. Sitagliptin, the recently approved dipeptidyl peptidase-4 (DPP-4) inhibitor is combined with metformin in two different dose configurations. Sitagliptin/metformin is marketed by Merck & Co., Inc as Janumet.
Marcolina ST. Nonpharmacologic management of migraines. Altern Med Alert 2007;10(6):61-65.
O'Mathuna DP. Antioxidant vitamins, immunity, and endurance exercise. Altern Med Alert 2007;10(6):66-69.
Greenfield RH. Tea time will never be the same again: Tea and milk. Altern Med Alert 2007;10(6):70-71. Greenfield RH. Adults, herbs, and evidence-based medicine. Altern Med Alert 2007;10(6):71-72. Greenfield RH. One does not equal twoCinnamon and diabetes mellitus. Altern Med Alert 2007;10(6):72.
National Institutes of Neurological Disorders and Stroke. Migraine headaches. Altern Med Alert 2007;10(suppl 6):S1-S2.
A simple questionnaire can identify individuals at risk for chronic kidney disease.
A new class of drug has been approved for the treatment of cutaneous T-cell lymphoma (CTCL) such as mycosis fungoides.
Persons who do not suffer hyperhidrosis (HID) may be surprised to learn that it has been associated with both occupational and physical impairment, as well as limitations in social interaction.
